NCT00157963已完成4 期
A 12 Week, Open, Randomized, Parallel, Multicenter Study of Efficacy, Tolerability & Safety of Hydrochlorothiazide (+) Losartan Potassium Versus Amlodipine in Essential Hypertensive Patients.
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 174
- 主要终点
- Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipine
研究概览
简要总结
An efficacy and safety study of hydrochlorothiazide (+) losartan potassium compared to amlodipine at week 12 in Korean patients with essential hypertension
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients of age 20 70 75 with essential hypertension
- •SiDBP 90 ~ 114mmHg at V1 & V2
排除标准
- •Patient has known or suspected secondary hypertension
- •Patient has a history of malignant hypertension (SiSBP > 210mmHg)
- •Individuals has a known sensitivity or intolerance to HCTZ or any AIIAs, or any sulfonamide-derived drugs.
- •Patient has shown significant abnormal laboratory evaluations
结局指标
主要结局
Antihypertensive efficacy of 12 weeks of treatment with hydrochlorothiazide (+) losartan potassium/amlodipine
次要结局
- Safety/Tolerability
研究者
相似试验
已完成
3 期
Hydrochlorothiazide as add-on to Olmesartan/Amlodipine in HypertensionEssential HypertensionNCT00902538Daiichi Sankyo2,204
已完成
1 期
Bioequivalence of Losartan and Hydrochlorothiazide (HCTZ) Combination Tablet and Coadministration of Its Components (0954A-306)HypertensionNCT00953680Organon and Co77
已完成
4 期
A comparison of losartan/hydrochlorothiazide vs high-dose angiotensin II receptor blocker(ARB) for uncontrolled hypertensive patientsHypertensionJPRN-UMIN000001389Kobe hypertensive study group193
已完成
4 期
Efficacy of Valsartan/Hydrochlorothiazide Versus Amlodipine and Hydrochlorothiazide in Patients HypertensionHypertensionNCT00425997Novartis480
已完成
3 期
A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential HypertensionEssential HypertensionNCT00667719Novartis564